drugset / Trial / NCT04297748
Bioimaging Study of 89Zr-M7824 in NSCLC
Phase 1/2
Terminated
5 enrolled
Olivia Newton-John Cancer Research Institute
Austin Health · collabMerck Healthcare KGaA · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a bioimaging study of 89Zr-M7824 PET scans in patients with advanced or metastatic non-small cell lung cancer who will be receiving M7824 alone or with standard of care chemotherapy. M7824 is a bifunctional fusion protein that combines an anti-PD-L1 antibody and the extracellular domain of TGFβ receptor II (TGFβRII) as a TGFβ neutralizing 'trap', into a single molecule.
Timeline
- Start
- 2020-06-01
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zirconium-M7824 | Diagnostic / imaging agent | 100 mg | Intravenous |
| Subject | Bintrafusp alfa | Protein / enzyme biologic | 1200 mg | — |